Navigation Links
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
Date:4/10/2012

A feedback from the US Food and Drug Administration (FDA) in June 2012. QRxPharma's US partner for MoxDuo IR, Actavis, Inc has the option to negotiate for the US license of MoxDuo CR pending achievement of certain MoxDuo IR sales milestones in the acute pain market.

MoxDuo CR is expected to launch into the US chronic pain market in 2015.

OxyContin® and MS Contin® are registered trademarks of Purdue Pharma L.P.

About MoxDuo CR
MoxDuo CR is a patented 3:2 ratio fixed dose combination of morphine and oxycodone designed to relieve moderate to severe chronic pain as a once- to twice-a-day formulation. The MoxDuo CR formulation contains proprietary technology to limit tampering or abuse by inhalation or solubilisation in water or alcohol.

About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. QRxPharma's lead product candidate, immediate release MoxDuo, has a Prescription Drug User Fee Act (PDUFA) date of 25 June 2012 when the New Drug Application review by the US Food and Drug Administration (FDA) will be completed. The Company recently signed a strategic partnership agreement with Actavis, Inc. to commercialise MoxDuo IR in the US acute pain market, with product launch anticipated in 3Q, CY2012. QRxPharma may co-promote its products in the US and plans to seek strategic partnerships for worldwide markets. Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo. For more information, vi
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to 80% ... pain can range from a dull, constant ache (chronic) to a sudden sharp pain ... steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative ...
(Date:6/30/2015)... Las Vegas, NV (PRWEB) , ... June 30, ... ... has recently returned to the U.S. after a 5-day tour in India. ... that are currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally ...
(Date:6/30/2015)... CT (PRWEB) , ... June 30, 2015 , ... ... on Wednesday, June 24, 2015 amidst bright skies and inspirational words. , ... the cherished processional walk from the Glenholme building to the school’s Center for ...
(Date:6/30/2015)... ... June 30, 2015 , ... Healthy and productive interpersonal ... outcomes. According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht ... to show “all kinds of behavior when the situation asks for it.” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson ... to Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) ... automate the workflow processes of the Revenue Cycle. , Provider XO, based in ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Dephinitive Systems Is Getting a New Name 2
... HealthDay Reporter , MONDAY, Jan. 23 (HealthDay News) -- Since ... questioned the safety of medical procedures used to terminate pregnancy. ... abortion is safer than carrying a baby to term. ... delivery is 8.8 deaths per 100,000, while the risk of ...
... world media, researchers, academics including several from Simon Fraser ... the Vancouver Convention Centre Feb. 16-20. , Simon Fraser University,s ... of a bell announcing the 2012 AAAS (American Association ... Aquarium yesterday. , "The AAAS conference is a must for ...
... MRI helps surgeons make more informed decisions about nerve-sparing ... new study published online in the journal Radiology ... most common cancer diagnosed in American men, according to ... prostatectomy, or removal of the prostate, is a common ...
... Jan. 24, 2012) For men diagnosed ... drug dutasteride ("Avodart") delays disease progression and initiating active ... a three-year international clinical trial led by Dr. Neil ... Network (UHN). The findings are published online ...
... Wakeling is adding to the arsenal of increasingly sophisticated ... viewing muscle activation details that have never been seen ... movement in people and animals, Wakeling has developed a ... proprietary data-processing software to scan and capture 3D maps ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Jan. ... be bad for you, a new study finds that parts of ... with others. It,s not clear how this effect of stress ... system -- which cause inflammation in the body -- have been ...
Cached Medicine News:Health News:Abortion Safer for Women Than Childbirth, Study Claims 2Health News:Abortion Safer for Women Than Childbirth, Study Claims 3Health News:SFU hits hot buttons at 2012 AAAS conference 2Health News:SFU hits hot buttons at 2012 AAAS conference 3Health News:Preoperative MRI may reduce risk of nerve damage in prostate cancer surgeries 2Health News:Prostate cancer study proves drug delays disease progression 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: